Follow
Subscribe via Email!

Enter your email address to subscribe to this platform and receive notifications of new posts by email.

Sickle Cell Anemia: How Mutated Hemoglobin Damages Red Cells

Sickle cell anemia is an inherited blood disorder caused by a mutation in the beta-globin gene. The resulting abnormal hemoglobin alters red blood cell shape, triggering painful vaso-occlusive crises and progressive organ complications.
A female doctor in a white coat consults with an older patient review notes together.

Sickle cell anemia is an inherited blood disorder where a genetic mutation alters the structure of hemoglobin, causing normally flexible red blood cells to stiffen into rigid crescent shapes. This shape change impairs blood flow through capillaries, depriving bodily tissues of oxygen and triggering recurrent episodes of pain known as vaso-occlusive crises. The condition is the homozygous and most common form of sickle cell disease, stemming from the inheritance of two mutant hemoglobin S alleles from carrier parents [2]. While healthy erythrocytes circulate freely for roughly 120 days, sickle cells break apart within 10 to 20 days, resulting in chronic hemolytic anemia and progressive multiorgan complications [15].

Molecular Roots of Hemoglobin S

Normal adult hemoglobin, designated as HbA, is a protein built from two alpha-globin and two beta-globin chains that bind oxygen in pulmonary capillaries and release it to peripheral tissues. In sickle cell anemia, a single nucleotide substitution in the HBB gene located on the short arm of chromosome 11 alters this molecular architecture. The mutation swaps adenine for thymine in the sixth codon of the beta-globin sequence, converting a GAG codon into a GTG codon [8, 10]. This single base change instructs cellular machinery to insert a hydrophobic valine amino acid in place of the normal hydrophilic glutamic acid at position 6 of the polypeptide chain [15].

This chemical difference was first identified in 1949, when physical chemist Linus Pauling and his Caltech colleagues Harvey Itano, Seymour J. Singer, and Ibert C. Wells used free-boundary electrophoresis to show that sickle hemoglobin moved with a different electrical charge than normal hemoglobin. Pauling dubbed it the first molecular disease. His team proved that an inherited defect in a single protein could produce widespread clinical illness. In 1956 and 1957, researcher Vernon Ingram at Cambridge University used protein fingerprinting to pinpoint the exact valine substitution in the beta-globin chain [15, 20].

Because human chromosomes come in pairs, an individual inherits one beta-globin allele from each parent. When a person receives one mutated gene and one normal allele, they have sickle cell trait, producing both normal adult hemoglobin and sickle hemoglobin without experiencing typical chronic symptoms. In contrast, inheriting two mutated alleles causes sickle cell anemia, leaving red blood cells devoid of normal adult beta-globin chains [9, 16].

Children smiling during community health outreach programs.
Community screening and health initiatives support children diagnosed with sickle cell disorders. (Credit: National Heart, Lung, and Blood Institute)

How Red Blood Cells Change Shape

The physical transformation of red blood cells depends on the presence of oxygen. When sickle hemoglobin binds oxygen in the lungs, the molecule stays dissolved as an isolated globular unit. But once erythrocytes travel into peripheral capillary beds and release their oxygen cargo, deoxygenated hemoglobin S undergoes a conformational shift that exposes the mutant valine residue [10]. This valine binds to a hydrophobic pocket on an adjacent beta-globin chain, initiating rapid stacking into long insoluble polymers [15].

These polymers do not form loose single strands. Instead, they assemble into alpha-helical bundles consisting of 14 parallel strands that twist together like a braided rope, stretching the erythrocyte membrane into a rigid crescent shape [10]. Although red cells can temporarily regain their normal disc shape upon reoxygenation in the pulmonary circuit, repeated cycles of sickling and unsickling cause progressive damage to the cell membrane [15].

Investigations led by Robert Hebbel at the University of Minnesota showed that repeated polymerization episodes cause the iron-bearing heme group to detach from hemoglobin and embed in the red cell membrane. This free iron catalyzes the formation of reactive oxygen species that degrade membrane lipids and proteins, leaving erythrocytes stiff and sticky. The damaged cells adhere to vascular endothelium and clump together, while their fragile membranes rupture prematurely, shortening erythrocyte lifespan from 120 days down to as few as four days [4, 10].

Why Sickle Cell Anemia Prevents Malaria

Despite the severe biological costs of sickle cell anemia, the sickle mutation persists at high frequencies in populations originating from tropical regions where malaria is endemic. In 1954, researcher Anthony Allison established that individuals with sickle cell trait possess substantial natural protection against fatal infection by Plasmodium falciparum, the deadliest malaria parasite [15, 18]. The geographic distribution of the HbS allele across sub-Saharan Africa, the Mediterranean basin, the Middle East, and parts of India matches historical maps of high malaria transmission [8, 19].

The evolutionary mechanism behind this protection relies on the unique intracellular environment of heterozygous red blood cells. When malaria parasites invade an erythrocyte containing sickle hemoglobin, the parasite consumes oxygen and produces acid metabolites, inducing local sickling that prompts the spleen to filter and destroy the infected cell before the pathogen can multiply. Furthermore, infected sickle cells produce higher quantities of heme oxygenase-1, an enzyme that generates carbon monoxide and suppresses the neuroinflammation that causes cerebral malaria [19]. Because children with the trait survive malaria outbreaks to reach reproductive age, positive natural selection has maintained the gene despite its recessive toll [15].

Doctor administering medication to a patient with sickle cell anemia.
A physician reviews daily medication regimens and preventive therapies with an adult patient. (Credit: Centers for Disease Control and Prevention)

Genetic sequencing shows that the sickle mutation arose independently at least five times throughout human evolutionary history. Restriction fragment length polymorphism studies by Y. W. Kan and Andreé Dozy in 1978 paved the way to map distinct beta-globin haplotype blocks, designated as Benin, Bantu, Senegal, Cameroon, and Arabian-Indian. A study of 98 patients in Georgia conducted by Hattori and colleagues identified the Benin haplotype in 54 percent of individuals, reflecting transatlantic migration patterns from West Africa [15].

Acute Pain Crises and Vaso-Occlusion

The defining clinical feature of sickle cell anemia is the vaso-occlusive crisis, an acute event triggered when rigid erythrocytes lodge in microvascular beds and obstruct capillary blood flow. The resulting local ischemia starves tissues of oxygen, causing sudden pain that commonly strikes the lower back, limbs, joints, and chest [14, 18]. Crises can last from several hours to several weeks and may be set off by exposure to cold weather, physical exhaustion, emotional stress, acidosis, or dehydration [6, 14].

In infants, the earliest manifestation of vaso-occlusion typically appears between 6 and 9 months of age as dactylitis, a painful swelling of the fingers and feet caused by bone marrow infarction in small extremities [4, 18]. Older children and adults frequently develop acute chest syndrome, a lung complication characterized by chest pain, fever, cough, wheezing, and pulmonary infiltrates on chest radiographs [1, 18]. Acute chest syndrome accounts for roughly 25 percent of all deaths related to sickle cell disease and requires emergency hospitalization with respiratory support and transfusions [18].

Two other acute crises can rapidly destabilize a patient’s health. Splenic sequestration occurs when large volumes of sickled erythrocytes become trapped in the spleen, causing the organ to engorge while circulating hemoglobin levels plunge into life-threatening territory; this event primarily affects young children around 1.4 years of age. In addition, infection with human parvovirus B19 can shut down red blood cell production in the bone marrow for up to a week, precipitating an aplastic crisis characterized by severe anemia and profound reticulocytopenia [18].

Father carrying young child on shoulders outdoors.
Carrier screening and genetic counseling assist families carrying the sickle cell trait. (Credit: Centers for Disease Control and Prevention)

Organ Complications in Sickle Cell Disease

Beyond acute emergencies, sickle cell disease inflicts cumulative ischemic damage on virtually every major organ system over a person’s lifetime. Repeated microvascular blockages within the spleen lead to tissue infarction and scarring, resulting in functional autosplenectomy by age five. Without a functioning spleen to clear encapsulated bacteria from the bloodstream, patients face high vulnerability to serious infections from Streptococcus pneumoniae, Haemophilus influenzae, and Salmonella species, which frequently cause bacterial osteomyelitis in infarcted bone [15, 18].

Cerebrovascular complications represent one of the most feared consequences of the disease, affecting 10 to 15 percent of pediatric patients through overt ischemic stroke. Silent cerebral infarcts, which leave visible lesions on neuroimaging without overt motor deficits, are roughly five times more common than symptomatic strokes and contribute to progressive cognitive impairment [18]. In the musculoskeletal system, repeated bone marrow ischemia causes avascular necrosis of the femoral and humeral heads, often requiring surgical hip or shoulder joint replacement in young adulthood [2, 15].

Chronic hemolytic vasculopathy also drives renal and pulmonary deterioration. Damaged filtration units in the kidneys cause hyposthenuria, hematuria, and progressive sickle nephropathy that can culminate in end-stage renal disease [18, 19]. In the lungs, vascular remodeling causes pulmonary hypertension in approximately 30 percent of adult patients, which places strain on the right ventricle of the heart and lowers life expectancy [10, 18]. Adult males may also experience priapism, an involuntary penile erection lasting over four hours that requires urgent urological intervention to prevent permanent erectile dysfunction [1, 15].

Biotechnology researchers developing genetic therapies in a laboratory setting.
Scientists develop transferrin antibody bioconjugates aimed at delivering RNA therapies to bone marrow. (Credit: BioPharma Dive)

Diagnostic Testing and Newborn Screening

Early diagnosis is essential because infants with sickle cell anemia can develop life-threatening bacterial infections and complications before their first birthday. Universal newborn screening programs, standard across the United States and the United Kingdom, evaluate blood collected from a newborn heel prick within days of birth [6, 14]. This testing identifies abnormal hemoglobin variants before clinical symptoms emerge, enabling the prompt initiation of prophylactic care [2, 17].

Laboratory confirmation relies on hemoglobin electrophoresis or high-performance liquid chromatography, both of which separate hemoglobin variants based on their distinctive electrical charges and chemical properties [12, 15]. A complete blood count typically reveals normocytic hemolytic anemia with elevated reticulocyte counts and increased unconjugated serum bilirubin [7, 15]. Prenatal diagnosis is also available through chorionic villus sampling at 10 to 12 weeks of gestation or amniocentesis at 15 to 18 weeks, allowing prospective parents with sickle cell trait to evaluate fetal genetics [6, 17].

For young children diagnosed with the condition, screening tools track stroke risk before arterial damage triggers physical symptoms. Annual transcranial Doppler ultrasound exams, recommended starting at age two, measure the velocity of arterial blood flow within major cerebral vessels. Elevated flow velocities indicate arterial narrowing and a high risk of stroke, prompting clinicians to initiate regular preventive blood transfusion regimens that significantly lower neurological morbidity [7, 18].

Managing Sickle Cell Anemia in Clinical Care

Clinical care for sickle cell anemia combines preventive medicine, daily pharmaceuticals, and routine monitoring to suppress acute crises and preserve organ function. To protect young children from fatal pneumococcal sepsis, pediatric guidelines advise daily prophylactic penicillin from diagnosis until at least five years of age, combined with pneumococcal and meningococcal immunizations [7, 11]. Families are also instructed to seek prompt medical evaluation whenever a child develops a fever exceeding 101.3 degrees Fahrenheit, or 38.5 degrees Celsius [1, 7].

The cornerstone of disease-modifying therapy remains hydroxyurea, an oral medication that reactivates the production of fetal hemoglobin, which is normally silenced shortly after birth [8, 17]. Because fetal hemoglobin lacks beta-globin chains and does not enter sickle polymer strands, higher HbF concentrations inhibit the stacking of hemoglobin S molecules, reducing the frequency of painful crises, episodes of acute chest syndrome, and transfusion requirements [8, 15]. Supportive medications like L-glutamine and crizanlizumab offer additional mechanisms to reduce vaso-occlusive frequency, whereas another drug, voxelotor, was voluntarily withdrawn from global markets by Pfizer in September 2024 after clinical monitoring indicated that its benefits did not outweigh observed patient risks [2, 7].

Sickle Cell Anemia: How Mutated Hemoglobin Damages Red Cells — NHLBI, NIH image
(Credit: NHLBI, NIH)

Blood transfusions play a central role in both acute stabilization and long-term prophylaxis against stroke. Simple top-up transfusions supply healthy donor erythrocytes during acute aplastic or sequestration crises, while automated red cell exchange transfusions replace sickled blood without elevating blood viscosity [13, 14]. However, repeated transfusions introduce excess iron that the human body cannot excrete naturally, necessitating iron chelation therapy to prevent toxic accumulation in the heart and liver [7, 13].

Curative Options Through Gene Editing

Historically, allogeneic bone marrow transplantation represented the only cure for sickle cell disease. Replacing a patient’s stem cells with marrow from a matched sibling donor allows the recipient to make healthy red blood cells [5, 17]. But fewer than 20 percent of patients have a matched sibling, and the transplant carries serious risks of infection and graft-versus-host disease [6, 15].

In December 2023, the U.S. Food and Drug Administration approved two cell-based gene therapies for patients aged 12 and older. The first therapy, Casgevy, developed by Vertex Pharmaceuticals, uses CRISPR/Cas9 genome editing in autologous stem cells to boost fetal hemoglobin; 29 of 31 evaluable trial patients (93.5 percent) remained free from severe pain crises for at least 12 consecutive months. The second therapy, Lyfgenia from Bluebird Bio, uses a lentiviral vector to insert an engineered anti-sickling gene, with 28 of 32 patients (88 percent) resolving crises, though it carries a boxed warning for hematologic malignancy [5].

Because both approved therapies require high-dose chemotherapy and cost millions of dollars, delivery remains difficult in regions like sub-Saharan Africa where most patients live [5, 16, 18]. To simplify treatment, startup Marrow Therapeutics raised $173 million in venture financing led by Scion Life Sciences. Led by chief executive Romesh Subramanian, the firm is developing MAR-101, a transferrin antibody bioconjugate that delivers small interfering RNA directly to bone marrow receptors through simple injection to reactivate fetal hemoglobin without chemotherapy conditioning [16].

Sources
  1. WEBSITE National Heart, Lung, and Blood Institute. (2024). Sickle cell disease symptoms. National Institutes of Health. [Article Link]
  2. WEBSITE National Heart, Lung, and Blood Institute. (2025). What is sickle cell disease? National Institutes of Health. [Article Link]
  3. WEBSITE National Library of Medicine. (2024). Sickle cell disease: MedlinePlus genetics. [Article Link]
  4. WEBSITE Cleveland Clinic. (2025). What is sickle cell anemia? [Article Link]
  5. PRESS RELEASE U.S. Food and Drug Administration. (2023). FDA approves first gene therapies to treat patients with sickle cell disease. [Article Link]
  6. WEBSITE Cleveland Clinic. (2025). What is sickle cell disease? [Article Link]
  7. WEBSITE National Health Service. (2026). Sickle cell disease. NHS UK. [Article Link]
  8. WEBSITE Scitable by Nature Education. (2010). Sickle-cell anemia: a look at global haplotype diversity. Nature Publishing Group. [Article Link]
  9. WEBSITE Centers for Disease Control and Prevention. (2024). What is sickle cell trait? [Article Link]
  10. WEBSITE Bridges, K. R. (2002). How does sickle cell cause disease? Information Center for Sickle Cell and Thalassemic Disorders, Brigham and Women’s Hospital and Harvard Medical School. [Article Link]
  11. WEBSITE Centers for Disease Control and Prevention. (2026). Prevention and treatment of sickle cell disease complications. [Article Link]
  12. WEBSITE U.S. Food and Drug Administration. (2019). FDA approves voxelotor for sickle cell disease. [Article Link]
  13. WEBSITE Guy’s and St Thomas’ NHS Foundation Trust. (2026). Simple blood transfusion: overview. [Article Link]
  14. WEBSITE Guy’s and St Thomas’ NHS Foundation Trust. (2026). Exchange blood transfusion: overview. [Article Link]
  15. WEBSITE National Library of Medicine. (2026). Sickle cell disease: MedlinePlus medical encyclopedia. [Article Link]
  16. ONLINE NEWS Wu, G. (2026). Marrow sets out to challenge genetic medicines for severe blood diseases. BioPharma Dive. [Article Link]
  17. WEBSITE American Society of Hematology. (2026). Sickle cell disease: patient resources and clinical overview. [Article Link]
  18. WEBSITE Wikipedia contributors. (2026). Sickle cell disease. Wikipedia, The Free Encyclopedia. [Article Link]
  19. WEBSITE Wikipedia contributors. (2026). Sickle cell trait. Wikipedia, The Free Encyclopedia. [Article Link]
  20. WEBSITE Wikipedia contributors. (2026). Sickle Cell Anemia, a Molecular Disease. Wikipedia, The Free Encyclopedia. [Article Link]
Leave a Comment

Related Posts
Total
0
Share